Study guide
10.2 Allergic & Irritant Contact Dermatitis: Pathogenesis, Investigation & Common Allergens
UEMS European Board of Dermatovenereology Diploma Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Structure, Eligibility & Examination Regulations
1.1 EBDVD Exam Format, Session Timing & Scoring Rules 1.2 Eligibility Routes, Application Requirements & Re-take Regulations 1.3 UEMS-EBDV Governance, European Training Requirements & Diploma Recognition
2 Chapter 2: Dermatologic Terminology, Lesion Morphology & Skin Biology
2.1 Skin Anatomy, Epidermal Biology & Barrier Function 2.2 Primary & Secondary Lesion Morphology 2.3 Cutaneous Immunology & Pathophysiological Reaction Patterns
3 Chapter 3: Dermatopathology & Diagnostic Procedures
3.1 Biopsy Selection, Processing & Special Staining Techniques 3.2 Major Histopathologic Patterns & Tissue Reaction Types 3.3 Direct & Indirect Immunofluorescence Microscopy
4 Chapter 4: Epidemiology, Photobiology & Occupational Dermatology
4.1 Epidemiological Principles & Cutaneous Disease Burden 4.2 Photobiology & Photoprotection 4.3 Occupational Dermatoses & Contact Sensitisation Surveillance
5 Chapter 5: Papulosquamous, Follicular & Adnexal Disease
5.1 Psoriasis: Variants, Psoriatic Arthritis, Comorbidity & European Management 5.2 Lichen Planus, Lichenoid Eruptions & Other Papulosquamous Disorders 5.3 Acne Vulgaris, Rosacea & Perioral Dermatitis 5.4 Hidradenitis Suppurativa, Hyperhidrosis & Other Sweat Gland Disorders
6 Chapter 6: Hair, Nails & Pigmentary Disorders
6.1 Hair Disorders: Non-Scarring & Scarring Alopecia, Hair Shaft Defects & Hirsutism 6.2 Nail Disorders, Onychomycosis & Nail Unit Tumours 6.3 Pigmentary Disorders: Vitiligo, Melasma & Other Hypo- and Hyperpigmentation
7 Chapter 7: Drug Reactions, Granulomatous & Deposition Disease and Skin Signs of Systemic Disease
7.1 Cutaneous Adverse Drug Reactions, SCARs & Dermatological Emergencies 7.2 Granulomatous & Deposition Disorders and Panniculitis 7.3 Skin Signs of Systemic Disease, Porphyrias, Nutritional Deficiency & Paraneoplastic Dermatoses
8 Chapter 8: Pruritus, Pregnancy & Geriatric Dermatology, Physical Injury and Mucosal Disease
8.1 Chronic Pruritus, Chronic Prurigo, Dermatoses of Pregnancy & Geriatric Dermatology 8.2 Burns, Cold, Heat & Radiation Injury and the Principles of Wound Healing 8.3 Oral Mucosal, Lip, Genital Mucosal & Perianal (Proctological) Disease
9 Chapter 9: Autoimmune Bullous Diseases
9.1 Pemphigus Group: Pemphigus Vulgaris, Foliaceus & Paraneoplastic Pemphigus 9.2 Pemphigoid Group & Epidermolysis Bullosa Acquisita 9.3 Dermatitis Herpetiformis & Linear IgA Bullous Dermatosis
10 Chapter 10: Eczematous Disorders, Urticaria & Allergology
10.1 Atopic Dermatitis: Pathogenesis, Phenotypes & European Management 10.2 Allergic & Irritant Contact Dermatitis: Pathogenesis, Investigation & Common Allergens 10.3 Urticaria, Angioedema & Cutaneous Mastocytosis 10.4 Immediate-Type Allergy: Diagnostics, Anaphylaxis, Food, Venom & Drug Allergy
11 Chapter 11: Connective Tissue Diseases & Cutaneous Vasculitis
11.1 Cutaneous Lupus Erythematosus Spectrum & Systemic Manifestations 11.2 Dermatomyositis, Systemic Sclerosis & Scleroderma Spectrum 11.3 Cutaneous Vasculitis & Neutrophilic Dermatoses
12 Chapter 12: Paediatric & Genetic Dermatology
12.1 Vascular Anomalies & Benign Neonatal Dermatoses 12.2 Hereditary Ichthyoses & Disorders of Keratinisation 12.3 Genodermatoses, Neurocutaneous Syndromes & Epidermolysis Bullosa
13 Chapter 13: Bacterial, Mycobacterial, Parasitic & Zoonotic Cutaneous Infections
13.1 Bacterial Skin & Soft Tissue Infections 13.2 Mycobacterial Infections: Cutaneous Tuberculosis, Leprosy & Atypical Mycobacteria 13.3 Parasitic Infestations, Arthropod Bites & Cutaneous Leishmaniasis 13.4 Lyme Borreliosis, Rickettsioses & Other Zoonotic and Travel-Related Skin Infections
14 Chapter 14: Viral & Fungal Cutaneous Infections
14.1 Herpesviridae Infections: HSV, VZV & HHV-8 14.2 Poxviruses & Human Papillomavirus Manifestations 14.3 Superficial, Subcutaneous & Deep Mycoses
15 Chapter 15: Sexually Transmitted Infections & Genital Infections
15.1 Syphilis: Pathogenesis, Clinical Stages, Serology & European Management 15.2 Neisseria gonorrhoeae, Chlamydia trachomatis & Genital Ulcer Diseases 15.3 HIV-Related Dermatoses, Partner Notification & Anogenital Lichen Sclerosus 15.4 Non-Gonococcal Urethritis, Mycoplasma genitalium, Trichomoniasis, Vaginal Infections & Balanitis
16 Chapter 16: Sexual Health Services, HIV Prevention & Anogenital Medicine
16.1 STI Epidemiology, Prevention, Services, Sexual History, HIV Testing, ART & PrEP/PEP 16.2 HPV-Related Anogenital Neoplasia, Cervical Screening & Common Gynaecological and Andrological Disorders 16.3 STIs in Pregnancy, Neonates & Children, Contraception, Sexual Health & Psychosexual Problems
17 Chapter 17: Keratinocyte Carcinomas, Precancerous Lesions & Other Skin Tumours
17.1 Actinic Keratoses, Bowen Disease & Field Cancerisation 17.2 Basal Cell Carcinoma: Subtypes, Risk Stratification & Management 17.3 Cutaneous Squamous Cell Carcinoma & Keratoacanthoma 17.4 Benign & Malignant Epidermal, Adnexal, Mesenchymal and Vascular Tumours, Cysts, Histiocytoses & Metastases
18 Chapter 18: Melanocytic Naevi & Melanoma
18.1 Benign Melanocytic Naevi: Acquired, Congenital, Spitz, Blue, Halo & Atypical Naevi 18.2 Melanoma Risk Factors, Clinical Presentation & Biopsy Protocol 18.3 Melanoma Histopathology, Breslow Thickness & Staging 18.4 Systemic Therapy for Advanced & Metastatic Melanoma
19 Chapter 19: Dermoscopy, Skin Imaging & Cutaneous Lymphomas
19.1 Dermoscopic Principles, Structures & Algorithmic Approaches 19.2 Dermoscopy of Non-Melanocytic Cutaneous Neoplasms 19.3 Non-Invasive Skin Imaging, Skin Function Measurement, Teledermatology & Skin Cancer Surveillance 19.4 Cutaneous Lymphomas, Merkel Cell Carcinoma & Cutaneous Sarcomas
20 Chapter 20: Dermatopharmacology, Systemic Therapeutics & Prescribing
20.1 Topical Corticosteroids, Calcineurin Inhibitors & Retinoids 20.2 Systemic Immunosuppressive & Biologic Therapies 20.3 Oral Retinoids & Phototherapy Modalities 20.4 Dermatological Prescribing: Anti-Infectives, Antihistamines, Antimalarials, Dapsone, Special Populations & Cutaneous Toxicity of Cancer Therapy
21 Chapter 21: Dermatosurgery, Cryotherapy, Lasers & Aesthetic Procedures
21.1 Surgical Anatomy, Local Anaesthesia & Excision Principles 21.2 Cutaneous Reconstructive Flaps, Skin Grafts & Surgical Complications 21.3 Cryosurgery, Electrosurgery & Cutaneous Lasers 21.4 Aesthetic & Corrective Dermatology, Photodynamic Therapy & Dermatological Radiotherapy
22 Chapter 22: Phlebology, Angiology, Psychodermatology & EBDVD Revision
22.1 Phlebology, Chronic Venous Insufficiency & Lower Extremity Ulcers 22.2 Angiology: Arterial Disease, Raynaud Phenomenon, Livedo, Thrombosis, Lymphoedema & Lipoedema 22.3 Psychodermatology, Delusional Infestation & Factitious Disorders 22.4 EBDVD Revision Strategy & Cross-Topic Review
10.2 Allergic & Irritant Contact Dermatitis: Pathogenesis, Investigation & Common Allergens
Key Takeaways Explain This Topic AI
Irritant Contact Dermatitis (ICD) is a non-immunologic physical or chemical disruption of the epidermal permeability barrier characterized by direct keratinocyte cytotoxicity, local release of preformed alarmins (IL-1alpha, TNF-alpha), and strict spatial demarcation confined to direct contact zones.
Allergic Contact Dermatitis (ACD) represents a true Type IV (cell-mediated, delayed-type) hypersensitivity reaction comprising an afferent sensitisation phase (hapten-carrier protein binding, Langerhans cell uptake, and lymph node T-cell priming) and an efferent elicitation phase (recruitment of memory T cells, spongiosis, and microvesiculation) that characteristically spills beyond the contact perimeter.
Diagnostic patch testing using the European Baseline Series (EBS) adheres to the International Contact Dermatitis Research Group (ICDRG) criteria, requiring standardized occlusive application on the upper back for 48 hours, with mandatory structured readings at 48 hours (Day 2), 72 hours (Day 3), and 96 hours to 7 days (Day 4–7) to detect delayed reactions.
Corticosteroid contact allergy represents an important diagnostic paradox wherein topical steroid therapy worsens or fails to clear chronic eczema; patch testing requires markers such as tixocortol pivalate and budesonide, with a mandatory delayed reading at Day 7 because early anti-inflammatory action suppresses initial erythema.
Photopatch testing is indispensable for diagnosing photoallergic contact dermatitis (e.g., from topical ketoprofen or organic sunscreen filters), utilizing duplicate test panels where one panel receives 5 J/cm² of broadband UVA radiation while the control panel remains dark.
Last updated: September 2026
- 10.2 Allergic & Irritant Contact Dermatitis: Pathogenesis, Investigation & Common Allergens
- Pathophysiological Divergence: ICD vs. ACD
Contact dermatitis accounts for the vast majority of occupational dermatoses in Europe. It is categorized into two fundamentally distinct entities: Irritant Contact Dermatitis (ICD) , representing approximately 80% of all contact eczema cases , and Allergic Contact Dermatitis (ACD) , accounting for the remaining 20% . ┌────────────────────────────────────────────────────────┐
- │ CONTACT DERMATITIS CAUSES │
- └───────────────────────────┬────────────────────────────┘
- │
- ┌──────────────────────────────┴──────────────────────────────┐
- ▼ ▼
- [IRRITANT CONTACT DERMATITIS (ICD)] [ALLERGIC CONTACT DERMATITIS (ACD)]
- Non-immunologic barrier destruction • Type IV delayed hypersensitivity (T-cell mediated)
- Universal susceptibility (dose-dependent) • Prior sensitisation required (hapten-specific)
- Direct cytotoxicity & alarmin cascade (IL-1α, TNF-α) • Two phases: Sensitisation (afferent) & Elicitation (efferent)
- Sharp demarcation limited to contact area • Spreads beyond contact margins; id reactions
- Burning / stinging pain > pruritus • Intense pruritus, spongiotic microvesicles
- Negative or irritant patch test • Positive patch test (++ or +++ at 48–96h)
- 1. Irritant Contact Dermatitis (ICD)
Mechanism: Non-immunologic, non-antigen-specific direct chemical or physical injury to the epidermal permeability barrier. Keratinocyte membranes are dissolved (by organic solvents or alkaline detergents), or cellular proteins are denatured (by strong acids, alkalis, or oxidizing agents).
Cellular Response: Injured keratinocytes rapidly release preformed pro-inflammatory alarmins ( IL-1α , IL-1β , TNF-α , and CXCL8/IL-8 ). This triggers immediate endothelial activation, capillary vasodilation, and an influx of neutrophils and monocyte-derived macrophages without requiring antigen-specific T-cell memory.
Exposure Patterns:
Acute Caustic ICD: Results from a single accidental exposure to a potent chemical agent (concentrated hydrochloric acid, sodium hydroxide). Manifests immediately with burning, stinging, erythema, epidermal necrosis, and chemical burns.
Cumulative / Chronic 'Wear-and-Tear' ICD: The far more common occupational variant. Caused by repeated, low-grade sub-threshold exposures to mild irritants (water, soaps, detergents, friction, wet work >2 hours/day). Gradual depletion of intercellular lamellar lipids and natural moisturizing factor overwhelms epidermal reparative capacity, leading to chronic scaling, cracking, and painful fissures.
2. Allergic Contact Dermatitis (ACD)
Mechanism: Classic Type IV (delayed-type, cell-mediated) hypersensitivity reaction . ACD requires previous epicutaneous sensitisation to an exogenous chemical agent and operates in two sequential immunological phases:
A. Sensitisation Phase (Afferent Limb)
Hapten Penetration & Conjugation: Low molecular weight chemical haptens ( <500 Daltons ) penetrate the intact stratum corneum. Haptens are not inherently immunogenic; they must covalently bind to endogenous epidermal self-proteins (e.g., serum albumin, cell surface molecules) to create complete hapten-protein neo-antigens .
Antigen Capture & Processing: Cutaneous antigen-presenting cells—principally epidermal Langerhans cells (CD1a+, CD207/Langerin+) and dermal dendritic cells—internalize the hapten-protein conjugate via macropinocytosis or receptor-mediated endocytosis. Under the influence of local keratinocyte-derived alarmins (IL-1β, TNF-α), Langerhans cells downregulate E-cadherin, detach from adjacent keratinocytes, and upregulate CCR7.
Lymph Node Migration: Guided by the chemokine ligand CCL21, Langerhans cells migrate through afferent dermal lymphatic vessels to the paracortical T-cell zone of regional draining lymph nodes.
T-Cell Priming & Clonal Expansion: Langerhans cells process the conjugate and present haptenated peptides on MHC Class II (to naive CD4+ helper T cells) or MHC Class I (via cross-presentation to naive CD8+ cytotoxic T cells). Co-stimulatory signaling (CD80/CD86 binding CD28) drives the proliferation of hapten-specific memory and effector T cells (predominantly Th1, Th17, and Tc1 cells). These memory cells express Cutaneous Lymphocyte-Associated Antigen (CLA) , CCR4, and CCR10, equipping them for homing back to the skin. This priming process takes 10 to 15 days and is clinically silent.
B. Elicitation Phase (Efferent Limb)
Re-Exposure & Recognition: Upon subsequent cutaneous re-challenge with the same hapten, the chemical penetrates and forms neo-antigens within hours.
T-Cell Recruitment: Antigen-presenting cells present the haptenated peptides to recirculating CLA+ memory T cells. Within 12 to 24 hours, recruited CD4+ and CD8+ memory T cells release massive amounts of pro-inflammatory cytokines, including Interferon-gamma (IFN-γ) , TNF-α , IL-17 , and IL-22 .
Spongiosis & Vesiculation: Keratinocytes undergo intercellular edema ( spongiosis ), stretching desmosomal junctions until microscopic and macroscopic intraepidermal vesicles form.
Temporal Peak: The clinical reaction develops over 24 to 48 hours , reaching maximum intensity at 48 to 72 hours post-exposure.
Diagnostic Comparison: ICD versus ACD
Clinical & Diagnostic Parameter Irritant Contact Dermatitis (ICD) Allergic Contact Dermatitis (ACD)
Immunological Basis Non-immunologic physical/chemical cytotoxicity Type IV cell-mediated delayed hypersensitivity
Host Susceptibility Universal (everyone reacts if dose is sufficient) Idiosyncratic (genetically/immunologically sensitized only)
Prior Sensitisation Not required; can occur on first contact Mandatory (requires 10–15 days afferent priming)
Onset of Manifestation Immediate (acute) or cumulative over weeks/months Delayed (24 to 72 hours following re-exposure)
Subjective Symptoms Burning, smarting, stinging, soreness > pruritus Intense, debilitating pruritus > burning
Anatomical Margins Strictly demarcated to exact contact zones Spills beyond contact margins ; spread to distant sites
Primary Lesion Morphology Glazed erythema, chapping, dryness, fissures, necrosis Erythema, edema, infiltrated papules, weeping vesicles
Patch Testing Result Negative or transient 'decrescendo' irritant reaction Positive allergic reaction showing 'crescendo' pattern
High-Yield Contact Allergens in European Testing
The European Baseline Series (EBS) represents the standardized panel of contact allergens tested across European dermatology clinics, curated continuously by the European Society of Contact Dermatitis (ESCD):
1. Nickel Sulfate (15%–20% Prevalence in European Females)
Exposure Sources: Costume jewelry, earring studs, jean buttons/rivets, watch buckles, mobile phones, spectacle frames, metal tools, and euro coins.
The EU Nickel Directive: Strict European legislation limits nickel release from metallic items in direct and prolonged contact with skin to <0.5 µg/cm²/week (and <0.2 µg/cm²/week for post assemblies inserted into pierced ears).
The Dimethylglyoxime (DMG) Spot Test: A classic diagnostic chemical test. Two drops of 1% dimethylglyoxime in ethanol plus two drops of 10% ammonium hydroxide are applied to a cotton swab and rubbed on the metal object. The development of a strawberry-pink precipitate indicates free nickel release exceeding the detection threshold (1:10,000), confirming potential allergenicity.
2. Potassium Dichromate (Hexavalent Chromium / Cr-VI)
Exposure Sources: Leather tanning (shoes, boots, leather sofas, jackets), wet construction cement, anti-rust paints, primers, and wood preservatives.
Pathophysiology: Hexavalent chromium [Cr(VI)] possesses superior trans-epidermal penetration compared to trivalent chromium [Cr(III)]. Once intracellular, Cr(VI) is enzymatically reduced to Cr(III), which acts as the ultimate hapten binding cellular proteins.
European Legislation: EU directives mandate the addition of reducing agents (such as ferrous sulfate ) to bagged cement to reduce soluble Cr(VI) to insoluble Cr(III) below 2 ppm (parts per million), dramatically reducing occupational cement eczema among European construction workers.
3. Cobalt Chloride
Exposure Sources: Metal alloys, ceramics, blue glass pigments, enamel, hard metal grinding tools, and orthopedic implants. Co-sensitization with nickel (found together in ores and plated jewelry) and chromate (cement) is exceedingly frequent.
4. Fragrance Mixes
Fragrance Mix I (FM I): Tested at 8% in petrolatum. Contains 8 distinct aromatic chemicals: oakmoss absolute , isoeugenol , eugenol , cinnamaldehyde , cinnamyl alcohol , geraniol , hydroxycitronellal , and alpha-amyl cinnamaldehyde , emulsified with sorbitan sesquioleate.
Fragrance Mix II (FM II): Formulated to capture newer fragrance sensitizers: citral , farnesol , coumarin , citronellol , alpha-hexyl cinnamaldehyde , and lyral (hydroxyisohexyl 3-cyclohexene carboxaldehyde).
Balsam of Peru ( Myroxylon pereirae ): A natural tree resin serving as a general screening marker for fragrance, spice, and flavor sensitivities.
5. Preservatives: Isothiazolinones and Formaldehyde Releasers
Methylchloroisothiazolinone / Methylisothiazolinone (MCI/MI, Kathon CG): Caused a massive European epidemic of allergic contact dermatitis in the 2010s.
Exposure Sources: Wet wipes (baby wipes), leave-on moisturizers, liquid hand soaps, shampoos, detergents, and water-based emulsion wall paints (frequently causing severe airborne allergic contact dermatitis when freshly painted rooms are occupied).
Regulatory Action: The European Commission banned MCI/MI in leave-on cosmetics and drastically lowered permitted concentrations in rinse-off products.
Formaldehyde Releasers: Preservatives that slowly release free formaldehyde to prevent bacterial spoilage: quaternium-15 (most potent sensitizer), diazolidinyl urea , imidazolidinyl urea , DMDM hydantoin , and bronopol .
6. Paraphenylenediamine (PPD)
Exposure Sources: Permanent oxidative black and dark hair dyes, fur dyeing, industrial rubber antioxidants, and temporary 'black henna' tattoos (natural henna is adulterated with high concentrations of PPD to yield an instant black stain and sharp definition).
Clinical Manifestation: Severe, acute, weeping contact dermatitis of the scalp, forehead, eyelids, and retroauricular folds; temporary black henna can produce blistering, keloidal scarring, and lifelong sensitization.
Cross-Reactivity with the 'Para-Group': Individuals sensitized to PPD often exhibit broad cross-reactivity with structurally related aromatic amines: ester-type local anesthetics ( procaine , benzocaine ), sulfonamides , sulfonylureas , para-aminobenzoic acid (PABA) sunscreens, and azo dyes.
7. Resins, Adhesives & Acrylates
Colophony (Rosin): Derived from pine tree resin ( Pinus palustris ). Present in medical adhesive tapes, sticking plasters, surgical dressings, violin bow rosin, soldering fluxes, cosmetics, and printing inks.
Epoxy Resin (Bisphenol A diglycidyl ether): Two-component heavy-duty adhesives, marine boat manufacturing, aerospace components, electrical insulation, and surface coatings.
Acrylates and Methacrylates (e.g., 2-hydroxyethyl methacrylate / 2-HEMA): Artificial UV-cured gel nail polish, dental bonding composites, orthopedic bone cement, and medical adhesive devices such as continuous glucose monitors (CGM) and insulin patch pumps.
8. Topical Corticosteroid Allergy: The Diagnostic Paradox
The Clinical Trap: Suspect contact allergy to topical corticosteroids when an eczematous dermatosis fails to clear, paradoxically worsens, or displays persistent edge flares during topical steroid application.
Diagnostic Markers:
Tixocortol pivalate: Primary screening marker for Group A corticosteroids (hydrocortisone type).
Budesonide: Primary screening marker for Group B (acetonides) and Group D (esters).
Mandatory Delayed Day 7 Reading: Corticosteroid patch tests frequently appear false-negative at 48 hours because the intrinsic anti-inflammatory action of the steroid molecule suppresses cutaneous erythema. As the local drug concentration wanes, cell-mediated elicitation manifests as a delayed positive reaction at Day 7 .
The Epicutaneous Patch Test Protocol
Patch testing represents the absolute gold standard for diagnosing Allergic Contact Dermatitis. [PATCH TESTING TIMELINE]
- DAY 0 (Monday) DAY 2 (Wednesday) DAY 4 (Friday) DAY 7 (Following Monday)
- ───────────────── ─────────────────── ──────────────── ──────────────────────────
- Apply chambers • Remove chambers • Second reading • MANDATORY LATE READING
- to upper back • Wait 20–30 mins • Evaluates delayed • Essential for: Corticosteroids,
- Standard EBS (resolve pressure) allergic reactions Neomycin, Gold salts
- Advise no shower • Initial first reading • Differentiates • Catches slow-eliciting
- or vigorous sweat • Mark reference points ICD from ACD delayed allergens
- Pre-Testing Prerequisites
Quiescent Skin: The patient must not have active dermatitis on the upper back (to prevent the 'angry back' or excited skin syndrome, which yields multiple false-positive irritant reactions).
Medication Washout: Discontinue potent topical corticosteroids on the back for at least 1 to 2 weeks . Discontinue systemic corticosteroids (prednisolone equivalent >10–15 mg/day) for at least 1 to 2 weeks. Topical calcineurin inhibitors should be withheld for 1 week.
Sunlight / Phototherapy: No UV exposure or phototherapy to the back within 4 weeks.
Technical Application and Schedule
Standardized allergens formulated in petrolatum or aqueous vehicles are loaded into specialized inert aluminum or plastic chambers (e.g., Finn Chambers, IQ Chambers) and secured to the healthy skin of the upper back on Day 0 (typically Monday) .
The patches remain in place under occlusion for 48 hours .
On Day 2 (Wednesday) , patches are peeled off. The skin is marked with a surgical dermographic pen and allowed to rest for 20 to 30 minutes until erythema from mechanical occlusion and tape removal subsides, followed by the first reading .
A second reading is performed on Day 3 or Day 4 (Thursday or Friday, 72–96 hours) . This reading is critical because allergic reactions characteristically show a crescendo pattern (increasing infiltration and vesiculation), whereas irritant reactions exhibit a decrescendo pattern (fading rapidly).
A delayed reading at Day 7 (following Monday) is mandatory for detecting slow-reacting allergens, notably topical corticosteroids , neomycin , and gold sodium thiosulfate .
ICDRG Patch Test Morphologic Grading Scale
- Score Symbol ICDRG Morphologic Description Clinical Interpretation
- No visible change Negative reaction
- ?+ Faint, macular erythema without palpable infiltration Doubtful reaction
- + Palpable erythema, infiltration, discrete small papules Weak positive (allergic) reaction
- ++ Strong erythema, infiltration, grouped papules, and small vesicles Strong positive (allergic) reaction
- +++ Intense erythema, severe edema, confluent bullae, or ulceration Extreme positive (allergic) reaction
IR Glazed, parchment-like erythema, follicular pustules, or superficial erosion sharply restricted to chamber rim Irritant reaction (non-allergic)
The Repeated Open Application Test (ROAT)
When a patch test yields a doubtful (?+) or weak (+) reaction, or when testing commercial leave-on products (e.g., cosmetics, moisturizers) containing complex mixtures at low concentrations, a Repeated Open Application Test (ROAT) is performed:
The patient applies the implicated commercial product twice daily to a 5x5 cm square of unaffected skin on the volar forearm for up to 14 to 21 consecutive days .
Development of an eczematous, pruritic plaque confirms clinical relevance and tolerance failure.
- Photopatch Testing
- Indications and Principle
Photopatch testing is indicated when a patient presents with an eczematous dermatosis strictly localized to photo-exposed anatomical zones (face, anterior 'V' of neck, dorsal hands, extensor forearms, sparing submental and retroauricular shadows), suggesting a photoallergic contact dermatitis .
In photoallergy, the chemical agent is not immunogenic in the dark; it requires photocactivation by ultraviolet radiation (almost universally broadband UVA , 320–400 nm) to convert the pro-hapten into an immunologically active complete hapten or to form photoproducts that bind carrier proteins.
Standard European Photopatch Protocol
Duplicate Sets: Two identical sets of photoallergens are applied to symmetric sides of the upper back on Day 0.
48-Hour Occlusion: After 48 hours (Day 2), both panels are uncovered. One panel is completely shielded with UV-opaque black material.
UVA Irradiation: The exposed panel is irradiated with a non-erythemogenic dose of broadband UVA (5 J/cm²) .
Readings: Both irradiated and non-irradiated control panels are evaluated at 48 hours (immediately post-UVA), 72 hours, and 96 hours .
Photopatch Interpretation Matrix
Photoallergic Reaction: Reaction (erythema, papules, vesicles) is observed exclusively on the UVA-irradiated panel , while the non-irradiated control panel remains completely negative.
Contact Allergic Reaction: Equal positive reactions appear on both the irradiated and non-irradiated panels (the substance is a contact allergen independent of light).
Combined Photoallergic and Contact Allergic: Positive reactions in both panels, but with significantly greater intensity and vesiculation on the irradiated panel .
High-Yield Photoallergens
Ketoprofen: Topical non-steroidal anti-inflammatory gel. Extremely high photosensitizing potency; known for severe cross-reactivity with the systemic lipid-lowering fibrate fenofibrate and the sunscreen benzophenone-3.
Organic UV Filters: Octocrylene , Benzophenone-3 (Oxybenzone) , Butyl methoxydibenzoylmethane (Avobenzone) .
Phenothiazines: Chlorpromazine , promethazine .